Bone-Marrow Transplantation in a Patient with Sickle-Cell Anemia
- 20 September 1984
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 311 (12) , 780-783
- https://doi.org/10.1056/nejm198409203111207
Abstract
SICKLE-CELL anemia affects 1 in 600 of the U.S. black population and accounts for 80,000 deaths annually throughout the world.1 , 2 Current therapy is designed to prevent sickle-cell crises, but supportive care remains the only treatment available once they occur. Attempts to alter the expression of hemoglobin genes in β-thalassemia and sickle-cell anemia with the use of azacytidine have produced only transient effects.3 This report describes the conversion of sickle-cell anemia to sickle-cell trait by marrow transplantation (done for treatment of leukemia) in a child with both sickle-cell anemia and acute myeloblastic leukemia. It raises the possibility of using marrow transplantation . . .Keywords
This publication has 4 references indexed in Scilit:
- 5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+ThalassemiaNew England Journal of Medicine, 1982
- Bone-Marrow TransplantationNew England Journal of Medicine, 1975
- Frequency of Sickling Disorders in U.S. BlacksNew England Journal of Medicine, 1973
- SICKLE CELL ANEMIA TERMINATING IN ACUTE MYELOBLASTIC LEUKEMIAAnnals of Internal Medicine, 1953